
Eligibility criteria:
Tumors, failure of or intolerance
ONCOLOGY, TUMORS
Eligible patients were aged 20-75 years with histologically confirmed CRC, failure of or intolerance to fluoropyrimidine and oxaliplatin treatment (those who showed relapse fewer than 6 months after administration of the final dose of adjuvant chemotherapy were also eligible), and no prior therapy with FTD/TPI and IRI. Additional inclusion criteria included an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, adequate organ function (bone marrow, liver, and kidney), and at least one measurable metastatic lesion assessed according to the revised Response Evaluation Criteria In Solid Tumors (RECIST), version 1.1.